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Abstract 
Background: Artemisinin combination therapy (ACT) is used worldwide as the first-line treatment against uncom-
plicated Plasmodium falciparum malaria. Despite the success of ACT in reducing the global burden of malaria, the 
emerging of resistance to artemisinin threatens its use.
Case report: This report describes the first case of failure of dihydroartemisinin-piperaquine (DHA-PPQ) for the 
treatment of P. falciparum malaria diagnosed in Europe. It occurred in an Italian tourist returned from Ethiopia. She 
completely recovered after the DHA-PPQ treatment but 32 days after the end of therapy she had a recrudescence. 
The retrospective analysis indicated a correct DHA-PPQ absorption and genotyping demonstrated that the same P. 
falciparum strain was responsible for the both episodes.
Conclusion: In consideration of the growing number of cases of resistance to ACT, it is important to consider a pos-
sible recrudescence, that can manifest also several weeks after treatment.
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Background
Artemisinin combination therapy (ACT) is used world-
wide as the first-line treatment against uncomplicated 
falciparum malaria [1]. Dihydroartemisinin-piperaquine 
(DHA-PPQ) is characterized by a post-treatment pro-
phylactic effect against re-infections that is longer than 
artemether-lumefantrine [2]. Despite the success of ACT 
in reducing the global burden of malaria, the emergence 
of resistance to artemisinin threatens its use. In Cam-
bodia, failure of ACT is now frequently observed [3, 4]. 
The increase of treatment failures and parasite clearance 
times observed soon after the widespread introduction 
of DHA-PPQ suggests a rapid emergence of resistance to 
both artemisinin and piperaquine components. In Asia, 
treatment failures have been reported in Myanmar [5]. In 
South America, data on (good) efficacy of DHA-PPQ is 
based on only one trial, conducted in Peru between 2003 
and 2005 [6]. In Africa, trials conducted in Burkina Faso 
[7], Kenya [8] and Angola [9] showed that DHA-PPQ was 
highly effective, with very rare cases of recrudescence 
invariably within 28 days.
Case report
A 72-year-old Italian woman was admitted on 26 
November, 2014 to the Centre for Tropical Diseases 
(CTD) of Negrar (Verona), for myalgias and arthralgias 
since 2 days, fever (up to 40 °C) and nausea since one day. 
She had visited Ethiopia (Omo River Valley) from 6 to 18 
November 2014. She was vaccinated against yellow fever, 
hepatitis A and B, but had not taken any malaria chemo-
prophylaxis. Her travel history included Ethiopia, Niger, 
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India, and Nambia, not South East Asia. Upon admission, 
her temperature was 38.3 °C, her weight 67.5 kg. Physical 
examination was unremarkable. The blood tests showed 
white blood cells (WBCs) 3.85  ×  109/L (normal range 
5.2–12.4 × 109/L), haemoglobin (Hb) 12.5 g/dL (normal 
range 14–18 × g/dL), platelets 46 × 109/L (normal range 
130–400 × 109/L), C-reactive protein 135 mg/L (normal 
range 0–5  mg/L), procalcitonin 14  μg/L (normal range 
0–0.5 μg/L). The quantitative buffy coat (QBC) test, anti-
gen malarial test and blood smears resulted positive for 
Plasmodium falciparum, with a parasitaemia of 0.3% 
(14,600/μL). The patient was treated with DHA-PPQ 
320/40 mg, three tablets/day for 3 days. The first day after 
treatment the parasitaemia dropped to 0.0023% (96/μL). 
After two days, the blood films and the QBC test resulted 
negative. Also, iv ceftriaxone 2 g/day was administrated 
for a left basal bronchopneumonia. The patient was dis-
charged on 5 December, 2014.
At a follow-up visit on 23 December, the QBC test and 
blood smears were still negative. The blood tests showed 
WBC 7.98 × 109/L, Hb 11.8 g/dL, platelets 233 × 109/L.
She was re-admitted on 7 January, 2015 complain-
ing of fever, nausea and vomiting that had started 7 days 
before (more than 4 weeks after anti-malaria treatment). 
The QBC test, antigen malarial test and blood smears all 
resulted positive again for falciparum malaria, with a par-
asitaemia of 0.4% (12,100/μL). WBCs were 5.5 ×  109/L, 
Hb 9.5 g/dL, platelets 96 × 109/L. The patient was treated 
this time with atovaquone-proguanil 250/100  mg, four 
tablets/day for 3  days. The parasitaemia decreased to 
0.36% (10,930/μL) 24  h after first dose of treatment, 
0.16% (5017/μL) the second day, 0.0016% (46/μL) the 
third day. After 4 days, blood films resulted negative. The 
patient was discharged on 12 January, 2015.
At follow-up visits 28 and 56  days after the second 
malaria episode, QBC and blood smears resulted nega-
tive and the main laboratory findings were normal.
The malaria-PCR performed a posteriori on a blood 
specimen collected on 23 December, 2014 resulted 
positive. Serum DHA-PPQ concentrations were retro-
spectively evaluated on cryo-preserved (−80  °C) sam-
ples taken on different days, during and after the drug 
administration, coupled with tandem-mass spectrom-
etry (Table 1). Limits of quantification for DHA and PPQ 
were 0.31 and 12.5 ng/mL, respectively. Pharmacokinetic 
data after the last dose of the three-day course of DHA 
and PPQ were comparable to data published by Nguyen 
et  al. [10] indicating no defect in drug absorption. PPQ 
serum concentration on day 7 was calculated on the basis 
of the drug elimination half-life in this patient. Calcu-
lated PPQ concentrations on day 7 showed a serum level 
of 110 ng/mL (levels below 30 ng/mL have been associ-
ated to a higher risk of recurrence of malaria) [11].
Genotyping of P. falciparum isolate(s) responsible for 
the patient’s infection was performed by amplification of 
three polymorphic markers, the merozoite surface pro-
tein 1 (msp1), merozoite surface protein 2 (msp2), and 
glutamate-rich protein (glurp) genes. These genes show 
a length polymorphism, allowing the detection of mul-
tiple infections by different P. falciparum genotypes [12, 
13]. Total genomic DNAs were extracted using PureLink 
Genomic DNA Kits-Invitrogen, from 200  µl of whole 
infected blood samples collected from the patient at the 
first (27 November, 2014) and second (7 January, 2015) 
hospital admittances. PCR amplified for msp1/msp2 and 
for glurp as described by Wooden et al. [12] and Viriya-
kosol et al. [13], respectively. Genetic characterization of 
the P. falciparum isolates showed the presence of a sin-
gle isolate responsible for the first episode and for the 
recurrence (Fig. 1). In order to investigate the resistance 
to the anti-malarial drugs of the isolate of P. falciparum 
infecting the patient, PCR amplification and sequenc-
ing were performed, in order to evaluate the presence of 
point mutations in the six molecular markers of P. falci-
parum (PfK13, Pfcrt, Pfmdr1, Pfdhfr, Pfdhps and PfCytB 
genes) linked to resistance to the artemisinin derivatives, 
quinolines, antifolates-cycloguanil and atovaquone. The 
polymorphism of the propeller domain of the Pfk13 gene 
Table 1 Serum concentrations of dihydroartemisinin-piperaquine
Piperaquine (ng/mL) Dihydroartemisinin (ng/nL) Hours since last administration
Day 1 132 0.74 10
Day 2 282 0.34 15
Day 3 234 1.34 15
Day 4 205 N.v. 39
Day 5 131 – 63
Day 28 18 – 591
Day 7 (calculated) 110 – 111
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was assessed as described by Taylor et  al. [14]. Analysis 
of Pfcrt/Pfdhps and Pfmdr1 and genes was performed as 
previously described in Menegon et al. [15] and Durais-
ingh et  al. [16], respectively. A fragment of Pfdhfr gene 
spanning codons 51–108 was analysed as described 
by Palmieri et  al. [17]. The presence of point mutation 
in PfCytB gene was evaluated as described in Kors-
inczky et  al. [18]. All PCR products were sent to Euro-
fins Genomics Company (Germany) for sequencing. 
The obtained sequences were compiled and analysed by 
Accelrys DS Gene software. The results are summarized 
in Table  2. Analysis of polymorphism of the P. falcipa-
rum isolates showed the presence of mutations in Pfcrt 
and Pfmdr1 genes linked to resistance to the quinolines 
and mutation in Pfdhfr and Pfdhps genes correlated to 
antifolate/cycloguanil resistance. No mutations associ-
ated with artemisinin resistance and atovaquone were 
detected.
Conclusion
This is the first case of failure of DHA-PPQ reported in 
Europe. The patient returned from Ethiopia, a country 
where DHA-PPQ failures have not been reported before. 
In this case, the rapid response to DHA-PPQ and the 
lack of mutations in the PfK13 gene suggest the involve-
ment of an artemisinin-sensitive strain. Although it was 
not possible to analyse a specific molecular marker of 
resistance to PPQ (a newly identified gene, PFE1085w 
is presumably associated to resistance to this drug) [19], 
the combination of results obtained from molecular and 
pharmacokinetic analyses and the clinical character-
istics support that the strain was resistant to the PPQ 
component.
In the last 2 years (July 2014 to June 2016) DHA-P was 
administered to 36 patients attended at the CTD for falci-
parum malaria, observing no other failure. These data are 
in agreement with the literature. The efficacy of DHA-
PPQ has been found very high, particularly in the African 
continent. There was a relevant delay between the onset 
of symptoms and the second diagnosis because the index 
of suspicion was low due to the negative laboratory tests 
performed at the 28-day follow-up visit. In consideration 
of the growing number of cases of resistance to ACT, it 
is important to consider a possible recrudescence, which 
can manifest several weeks after treatment.
Fig. 1 Genotyping of Plasmodium falciparum isolates responsible for 
the patient’s infection. M DNA ladder; A sample November 27, 2014; B 
sample January 7, 2015; C positive control; D negative control
Table 2 Analysis of the molecular markers of P. falciparum linked to drug resistance
Specific point mutations in Pfcrt and Pfmdr1 gene are linked to quinoline-based antimalarial resistance; PfK13 is the molecular markers for artemisinin resistance; 
mutation I258M and Y268F/S in PfCytB gene are linked to atovaquone resistance; mutations in Pfdhfr/Pfdhps genes are responsible for P. falciparum resistance to 
antifolate-cycloguanil
Marker PfK13
codon 74 75 76 97 86 184 1034 1042 1246 580 258 268 51 59 108 436 437 540 581 613
M N K H N Y S N D C I Y N C S S A K A A
atg aat aaa cac aat tat agt aat gat tgt aat tat aat tgt agc tct gct aaa gcg gcc
I E T Y Y F C D Y Y M F/S I R N A/F G E G S/T
a gaa aca tac tat t tgt gat tat tat atg t/tgt aat cgt aac gct/t ggt gaa ggg tcc/acc
I E T H N Y S N Y C I Y N R N S G E A A
a gaa aca cac aat tat agt aat tat tgt aat tat aat cgt aac tct ggt gaa gcg gcc
I E T H N Y S N Y C I Y N R N S G E A A
a gaa aca cac aat tat agt aat tat tgt aat tat aat cgt aac tct ggt gaa gcg gcc
Wild type
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